Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 avr. 2026 11h51 HE | Source: Research and Markets

Global Tumor Models Market Set to Soar from $2.37B in 2026 to $3.57B by 2030 - 3D Spheroids and Organ-on-a-Chip Propel Tumor Model Advancements

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Tumor Models Market Report 2026" has been added to ResearchAndMarkets.com's offering. The tumor models market has been experiencing rapid growth,...
02 avr. 2026 11h49 HE | Source: Research and Markets

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Intelligence Report 2026-2030: Industry Growth Driven by Personalized Treatment Adoption

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers a...
02 avr. 2026 10h47 HE | Source: Research and Markets

Metastatic Lung Adenocarcinoma Treatment Market Outlook Report 2026-2030: Targeted Therapies Fuel Growth, with Revenues Reaching $5 Billion by 2030

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Metastatic Lung Adenocarcinoma Treatment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The metastatic lung...
01 avr. 2026 05h26 HE | Source: Research and Markets

Oncology Ablation Market Trends and Investment Opportunities, 2026-2030 & 2035

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Oncology Ablation Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive statistics, market size...
31 mars 2026 07h20 HE | Source: Research and Markets

Oncologists Industry to Grow by $4 Billion Globally During 2026-2030: Assessment of the Lucrative Trends and Opportunities by Region

Dublin, March 31, 2026 (GLOBE NEWSWIRE) -- The "Oncologists Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides comprehensive statistics, including global...
30 mars 2026 05h05 HE | Source: Research and Markets

Non-Small Cell Lung Cancer (NSCLC) Global Market Trends and Regional Growth Insights 2026-2030: Rapid Adoption of Targeted Therapies and Immunotherapy Fuels Market Expansion, Reaching $70.8 Billion by 2030

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Non-Small Cell Lung Cancer (NSCLC) Market Report 2026" has been added to ResearchAndMarkets.com's offering. The non-small cell lung cancer...
30 mars 2026 04h28 HE | Source: Research and Markets

Cancer Clinical Decision Tools Market to Grow by $280 Million During 2026-2030: Key Growth Areas & Competitive Strategies Identified

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Cancer Clinical Decision Tools Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global cancer clinical decision tools...
27 mars 2026 10h49 HE | Source: Research and Markets

Anti-Cancer MAbS Market Report 2026-2030 Featuring Strategic Analysis of Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, Roche, GlaxoSmithKline and Other Key Players

Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "Anti-Cancer MAbS Market Report 2026" has been added to ResearchAndMarkets.com's offering. The anti-cancer monoclonal antibodies (mAbs) market has...
24 mars 2026 06h45 HE | Source: BioNTech SE

BioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs

Präsentationen zeigen Fortschritte in BioNTechs spätklinischen Programmen im Bereich Lungenkrebs und unterstreichen das Potenzial des differenzierten Unternehmensportfolios, welches Immunmodulatoren,...
24 mars 2026 06h45 HE | Source: BioNTech SE

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates,...

Page suivante